gliptin

gliptin

Any of a class of drugs that are inhibitors of the enzyme dipeptidyl peptidase-4 (DPP-4). Members of this class include sitagliptin and saxagliptin and are used to treat type 2 diabetes mellitus. Synonym: dipeptidyl peptidase-4 inhibitor
References in periodicals archive ?
Glenmark's Teneligliptin is the lone gliptin which is obtainable at lowest cost among all other gliptins being marketed in India whereas other gliptins are currently being imported.
By offering Teneligliptin at this price, we aspire to bring many more patients in the advanced gliptin therapy fold".
Thus the launch of these 2 products will lower the daily cost of treatment for a Diabetes patient on gliptin therapy by about 55%.
Some of the new DPP-4 inhibitors--the gliptin class of hypoglycemics--can interact with antiretrovirals.
1]( CA rdiovascular Safety & R enal M icrovascular outcom E study with LINA gliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk) trial will investigate the effect of the once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on cardiovascular and renal outcomes in adults with type 2 diabetes (T2D) at risk of major macro- and microvascular events.
A multicenter, international, randomized, parallel group, double-blind, placebo-controlled CA rdiovascular Safety & R enal M icrovascular outcom E study with LINA gliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk.
A gliptin is an excellent option in an obese patient with type 2 diabetes whose [HbA.
Colesevelam and the incretin-enhancing gliptins have established roots in the treatment of type 2 diabetes, but preliminary evidence shows clinical benefit in type 1 disease.
There are three incretin-enhancing gliptins on the market, all with an indication for improvement of glycemic control in type 2 diabetes: sitagliptin (Januvia), saxagliptin (Onglyza), and linagliptin (Tradjenta).
Usually, we prescribe drugs such as metfornin, gliptin and byetta which balances the weight gain side effects of antidiabetic drugs," says Dr Ambrish Mittal, chairman, Endocrinology, Medanta - The Medicity.
A second abstract published in the ADA's abstract book for the conference highlights the characteristics of people with T2D at high CV risk or with CV complications enrolled in the CAROLINA ( CAR diovascular O utcome Study of LINA gliptin versus Glimepiride in Early Type 2 Diabetes) study.